25 research outputs found
Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001–2002
SummaryObjectivesRecognizing the uniqueness of secondary dengue virus (DENV)-1/3 dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) cases at an interval of 24 years, we sought to estimate DENV infections as well as the ratios between mild disease and DHF/DSS by DENV infection sequence in Playa District (Havana, Cuba) during the 2001–2002 outbreak of dengue virus type 3 (DENV-3).MethodsA retrospective seroepidemiological study was conducted in 2003 in Playa District. Blood samples were collected from a 1% random sample of residents and were studied for the prevalence of dengue neutralizing antibodies.ResultsDENV-3 was found to have infected 7.2% (95% confidence interval (95% CI) 6.0–8.4%) of susceptible individuals (the entire cohort), the majority of whom experienced silent infections. Virtually every individual who had a secondary infection in the sequence DENV-1 then DENV-3 became ill, with a ratio of severe to mild cases of 1:35 (95% CI 1:67–1:23). Secondary infections in the sequence DENV-2/3 were less pathogenic than DENV-1/3. Mild disease accompanying secondary DENV2/3 occurred at a ratio of 1:4.49 infections (95% CI 1:5.77–1:3.42) secondary infections.ConclusionsThe results obtained highlight the role of the infecting serotype and also the sequence of the viral infection in the clinical outcome of a dengue infection
Research Priorities for Neglected Infectious Diseases in Latin America and the Caribbean Region
Dujardin, J. C. et al. 5 p.-1 tab.Global priorities for research in neglected
infectious diseases (NIDs) can be assessed
in different ways, but it is important to
realize that regional priorities may significantly
differ one from another. The region
of Latin America and the Caribbean (LAC)
is—along with Africa and Asia—more
affected by NIDs than other regions of the
world. Some of the Latin American NIDs
are common to other continents, while
others are very specific or disproportionately
affect the Latin American region [1–
3] (Table 1). Because of its huge ecological
diversity, ongoing environmental changes,
and massive migrations, LAC is also a
catalyst for the (re-)emergence and spreading
of NIDs, both inside and outside the
subcontinent. Following a colloquium on
NIDs in LAC held in Lima, Peru, between
12 and 14 November 2009, a thematic
workshop was organized with the support
of the European Commission (EC). It
involved 29 scientists (16 from the Americas,
two from the Democratic Republic of
Congo and India, respectively, and nine
from Europe) working on different NIDs
and representing several research areas
from basic to applied. This report summarizes
the consensus comments of the expert
group after oral and written consultation. It
is envisaged that this document should
stimulate a debate within the scientific
community and serve as a recommendation
for future actions by international or
regional funding agencies in the area of
NIDs in LACThis work was supported by the Directorate-General for Development Cooperation of the Belgian Government (framework agreement 03, project 95502) and the European CommissionPeer reviewe
Research priorities for neglected infectious diseases in Latin America and the Caribbean Region
Global priorities for research in neglected infectious diseases (NIDs) can be assessed in different ways, but it is important to realize that regional priorities may significantly differ one from another. The region of Latin America and the Caribbean (LAC) is—along with Africa and Asia—more affected by NIDs than other regions of the world. Some of the Latin American NIDs are common to other continents, while others are very specific or disproportionately affect the Latin American region [1– 3] (Table 1). Because of its huge ecological diversity, ongoing environmental changes, and massive migrations, LAC is also a catalyst for the (re-)emergence and spreading of NIDs, both inside and outside the subcontinent. Following a colloquium on NIDs in LAC held in Lima, Peru, between 12 and 14 November 2009, a thematic workshop was organized with the support of the European Commission (EC). It involved 29 scientists (16 from the Americas, two from the Democratic Republic of Congo and India, respectively, and nine from Europe) working on different NIDs and representing several research areas from basic to applied. This report summarizes the consensus comments of the expert group after oral and written consultation. It is envisaged that this document should stimulate a debate within the scientific community and serve as a recommendation for future actions by international or regional funding agencies in the area of NIDs in LAC.
(Párrafo extraído del texto a modo de resumen)Facultad de Ciencias Médica
Dengue: where are we today?
Dengue is considered the main arthropod-borne viral disease of humans.
In the last few years, an increasing number of reports of mild and
severe cases have been reported. The growing dengue incidence observed
in recent years has been accompanied by reports of new observations,
findings and global initiatives with an improvement in our
understanding of this phenomenon. The epidemiology and new clinical
classification of dengue, advances in the diagnostic and pathogenesis
knowledge, and vaccine development as well as control methods including
new global initiatives are summarised here
Sequential infection as risk factor for dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) during the 1981 dengue hemorrhagic cuban epidemic
RESEARCH NOTE - Absence of Antibody-dependent Enhancement (ADE) of Viral Infectivity in the Epidemic Neuropathy in Cuba
Fatal dengue hemorrhagic fever in Cuba, 1997
AbstractObjectives: After more than 15 years without dengue activity, a dengue II epidemic was reported in Cuba in 1997. Three thousand and twelve serologically confirmed cases were reported, with 205 dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) cases and 12 fatalities. This report presents the clinical, serologic, and virologic findings in the 12 fatal DHF/DSS cases.Methods: Serum and necropsy samples were studied by viral isolation in C636 cell line and polymerase chain reaction. Serum samples were tested by IgM capture enzyme-linked immunoassay (ELISA) and ELISA inhibition method (EIM).Results: All 12 cases were classified as DHF/DSS according to the Pan American Health Organization Guidelines for Control and Prevention of Dengue and Dengue Hemorrhagic Fever in the Americas. All patients were older than 15 years. Women were more frequently affected. The symptoms and signs presented by these patients were similar to those previously described in DHF/DSS cases. Clinical deterioration occurred on average at day 3.75. Abdominal pain and persistent vomiting were the earliest and most frequent warning signs. Dengue infection was confirmed in all cases. IgM antibodies were detected in 11 of 12 cases, all of them with a secondary infection. Dengue II virus was detected by viral isolation in 12 samples and by polymerase chain reaction in 17. Virus or RNA was detected in various tissues, including kidney, heart, lung, and brain.Conclusion: The clinical, pathologic, and laboratory features of 12 cases of fatal dengue hemorrhagic fever were reviewed. The results obtained demonstrate that adults with a primary dengue infection are at risk of developing the severe disease ( (DHF) if they are infected with a different serotype
Neutralising antibodies after infection with dengue 1 virus
Severity of disease is markedly increased when infection with dengue virus type 2 (DENV-2) follows infection with DENV-1 at an interval of 20 years. Studies have shown that heterologous neutralizing antibody titers are inversely correlated with severity of a second infection. If this mechanism controlled disease severity in Cuba, heterotypic antibody titers should have declined over time. To determine whether phenotypic changes in dengue antibodies occur over time, we analyzed serum samples collected 4–8 and 20–22 years after DENV-1 infection. We found a significant increase in mean titer of homologous DENV-1 neutralizing antibodies and a significant decrease in heterologous antibodies to 1 of 2 genotypes of DENV-2 virus (the American genotype). Asian DENV-2 viruses were not neutralized during either interval; however, the American genotype underwent phenotypic changes in heterotypic viral neutralizing antibodies in the predicted direction. This finding may be related to the time-dependent changes in severity of disease found with secondary dengue infection